# Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients

> **NCT00122577** · PHASE2 · TERMINATED · sponsor: **French National Agency for Research on AIDS and Viral Hepatitis** · enrollment: 50 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Tenofovir
- **DRUG:** Atazanavir
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT00122577
- **Lead sponsor:** French National Agency for Research on AIDS and Viral Hepatitis
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-03
- **Primary completion:** —
- **Final completion:** 2004-07
- **Target enrollment:** 50 (—)
- **Last updated:** 2005-07-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00122577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00122577, "Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00122577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*